Novavax (NVAX) Interest Expenses (2010 - 2026)

Novavax's Interest Expenses history runs 17 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 14.36% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $21.7 million (changed 0.18% YoY), while the FY2025 annual figure was $22.5 million, up 12.31% from the prior year.
• Interest Expenses was $4.9 million for Q1 2026 at Novavax, down from $5.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $7.6 million in Q4 2024 to a low of $2.9 million in Q3 2023.
• Historically, Interest Expenses has averaged $4.8 million across 5 years, with a median of $4.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses slumped 49.89% in 2023, then surged 84.24% in 2024.
• A 5-year view of Interest Expenses shows it stood at $4.6 million in 2022, then slipped by 10.52% to $4.1 million in 2023, then soared by 84.24% to $7.6 million in 2024, then retreated by 23.22% to $5.8 million in 2025, then dropped by 15.85% to $4.9 million in 2026.
• The last three Interest Expenses figures came in at $4.9 million (Q1 2026), $5.8 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.